GMCI plus Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC Patients

Brief description of study

The purpose of the trial is to assess the safety and efficacy of the Gene Mediated Cytotoxic Immunotherapy (GMCI) added to standard of care immune checkpoint inhibitor (ICI) for non-small Cell Lung Cancer (NSCLC) patients. We want to know if GMCI can increase the number of patients who will respond to the continued ICI. Patents may receive whatever standard of care therapy as indicated by their disease such as maintenance chemotherapy, bevacizumab , or focal radiation.


Clinical Study Identifier: s19-01928
ClinicalTrials.gov Identifier: NCT04495153
Principal Investigator: Daniel H. Sterman.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.